STI-2020 clinical trials
Also written COVI-AMG, STI-2020, COVI-DROPS and STI-2099.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses STI-2020 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2021 (6)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses STI-2020 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)TerminatedPhase 2Sorrento Therapeutics, Inc.NCT04900428Written as COVI-DROPSHow we know
- Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adults With COVID-19WithdrawnPhase 2Sorrento Therapeutics, Inc.NCT04771351Written as COVI-AMGHow we know
- Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 SymptomsWithdrawnPhase 2Sorrento Therapeutics, Inc.NCT04734860Written as COVI-AMGHow we know
- Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19WithdrawnPhase 1/2Sorrento Therapeutics, Inc.NCT04738175Written as COVI-AMGHow we know
- Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)CompletedPhase 2Sorrento Therapeutics, Inc.NCT04906694Written as COVI-DROPSHow we know
- Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 InfectionWithdrawnPhase 2Sorrento Therapeutics, Inc.NCT05074394Written as COVI-DROPSHow we know
- Study to Evaluate the Safety, Pharmacokinetics and Efficacy of STI-2020 (COVI-AMG™) in Outpatients With COVID-19WithdrawnPhase 1/2Sorrento Therapeutics, Inc.NCT04584697Written as COVI-AMGHow we know
Codes
What other systems call STI-2020 · ClinicalTrials.gg INT001573
- MeSH (NLM) C000714227STI-2020One source NLM
- UNII (FDA) 12U14K0SR5PLUTAVIMABConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000714227 | STI-2020 | One source NLM |
| UNII (FDA) | 12U14K0SR5 | PLUTAVIMAB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.